Invivyd vs Nektar Therapeutics
Invivyd and Nektar Therapeutics are similar in size: $53.4m and $55.2m of revenue in their latest fiscal years. Invivyd grew faster (110.5% against -43.9%). Invivyd kept more of each dollar of sales as profit: a net margin of -98.2% against -297.1%. Invivyd carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | InvivydIVVD, 2025 | Nektar TherapeuticsNKTR, 2025 |
|---|---|---|
| Revenue | $53.4m | $55.2m |
| Revenue growth | 110.5% | -43.9% |
| Net income | −$52.5m | −$164m |
| Operating margin | -104.0% | -253.7% |
| Net margin | -98.2% | -297.1% |
| Return on equity | -34.0% | — |
| Free cash flow | −$58.3m | −$209m |
| Cash | $227m | $15.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 122 | 63 |
| Market value | $169m | $765m |
| Price vs our value range | — | — |
| Moat score | — | 18 (Weak) |
| Insider trades, 12 months | 1 buys, 20 sales | 0 buys, 16 sales |